2024-04-18  5:35:05 PM Chg. -27.0000 Volume Bid6:30:00 PM Ask6:30:00 PM Market Capitalization Dividend Y. P/E Ratio
1,524.0000GBX -1.74% 178,070
Turnover(GBP): 2.72 mill.
-Bid Size: - -Ask Size: - 2.1 bill.GBP - -

Business description

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.
 

Management board & Supervisory board

CEO
Mark Crossley
Management board
Ryan Preblick, Christian Heidbreder, Cindy Cetani, Hillel West, Jon Fogle, Kathryn Hudson, Richard Simkin, Vishal Kalia, Jeffrey Burris
Supervisory board
Graham Hetherington, Jerome Lande, Joanna Le Couilliard, Juliet Thompson, Mark Crossley, Mark Stejbach, Peter Bains, Ryan Preblick, Keith Humphreys, Barbara Ryan
 

Company data

Name: Indivior PLC
Address: 103-105 Bath Road,UK-Slough, SL1 3UH UK, Berkshire
Phone: +44-1753-217800
Fax: +44-1753-217899
E-mail: -
Internet: indivior.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 56.31%
IPO date: -

Investor relations

Name: Jason Thompson
IR phone: +1-804-402-7123
IR Fax: -
IR e-mail: investorrelations@indivior.com

Main Shareholders

Individuals
 
92.83%
Bank or Nominees
 
6.15%
Others
 
0.93%
Investment Trust
 
0.08%
Insurance Company
 
0.01%